Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.12−1.38 (-7.89%)
Close on Nov 13, 2026Market cap $117.10MP/E –Yield –
Cue Biopharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Cue Biopharma's total debt was $100.00K at Mar 31, 2025. For fiscal 2024 it was $37.00K, down 99.6% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $37.00K | -99.6% |
| FY2023 | Dec 31, 2023 | $8.24M | -18.5% |
| FY2022 | Dec 31, 2022 | $10.11M | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | $100.00K | -98.6% |
| Q4 FY2024 | Dec 31, 2024 | $37.00K | -99.6% |
| Q3 FY2024 | Sep 30, 2024 | $5.33M | -41.8% |
| Q2 FY2024 | Jun 30, 2024 | $6.29M | -37.9% |
| Q1 FY2024 | Mar 31, 2024 | $7.28M | -27.7% |
| Q4 FY2023 | Dec 31, 2023 | $8.24M | -18.5% |
| Q3 FY2023 | Sep 30, 2023 | $9.16M | -8.7% |
| Q2 FY2023 | Jun 30, 2023 | $10.12M | +2.1% |
| Q1 FY2023 | Mar 31, 2023 | $10.08M | +2.2% |
| Q4 FY2022 | Dec 31, 2022 | $10.11M | – |
| Q3 FY2022 | Sep 30, 2022 | $10.03M | – |
| Q2 FY2022 | Jun 30, 2022 | $9.91M | – |
| Q1 FY2022 | Mar 31, 2022 | $9.86M | – |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
See a number that looks wrong?